Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Speciality: Oncology
Description:
Welcome to our podcast on Evidence-Based Oncology—a practice that’s transforming cancer care worldwide. Evidence-based oncology means making clinical decisions grounded in the latest and most reliable research, rather than tradition or anecdote. This approach ensures that patients receive treatments proven to be effective, personalised to their unique situations. By analysing large-scale clinical trials and real-world data, oncologists can identify which therapies work best for specific cancers and patient populations. Ultimately, evidence-based practice leads to better outcomes, fewer side effects, and more efficient use of healthcare resources. As research continues to advance, evidence-based oncology promises a future where every patient receives the right care at the right time.
See More Webinars @ Hidoc Webinars
1.
Chemo causes lasting physical decline in breast cancer survivors
2.
No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma
3.
In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events
4.
Which women need more than mammograms for breast cancer screening?
5.
Cancer research in the US is world class. With the government pulling out, its future is uncertain
1.
Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care
2.
Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control
3.
Prevention of Thrombotic Complications in High-Risk Patients
4.
Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment
5.
Personalized Survivorship Navigation in Precision Cancer Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
5.
Case-Based Learning: Oncology
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge